Thanks for joining us for Eli Lilly and Company's Q3 2024 earnings ... Our manufacturing expansion agenda remains a top priority. In September, we invested nearly $2 billion to increase our ...

Eli Lilly and Company reported third quarter results and missed expectations and had to lower its guidance, which was a huge disappointment for investors. But in the last few years, Eli Lilly was ...

Lilly's shares fall 8% as drug sales miss expectations CEO David Ricks cited physical and financial constraints at wholesalers for the shortfall Lilly slashes annual profit forecast due to ...

Eli Lilly on Wednesday fell short of profit and revenue expectations for the third quarter, weighed down by disappointing sales of its blockbuster weight loss drug Zepbound and diabetes treatment ...

Copyright 2024 The Associated Press. All Rights Reserved. FILE - This April 26, 2017 file photo shows the Eli Lilly & Co. corporate headquarters in Indianapolis. (AP ...

AJ Mast / Bloomberg via Getty Images Eli Lilly (LLY) shares tumbled 12% at the opening bell Wednesday after its third-quarter results fell well short of analysts' estimates and it lowered its full ...

Drug maker Eli Lilly’s share price plunged Wednesday morning after the company reported worse third-quarter results than expected, especially in its weight-loss drug division, registering a rare ...

Eli Lilly reported Q3 revenue and earnings that fell short of analysts' expectations. Mounjaro and Zepbound faced challenges as U.S. wholesalers reduced inventories of the drugs. The bull case for ...

Eli Lilly has dropped (PDF) the lead candidate from its $2.4 billion takeover of Dice Therapeutics, shifting the focus of its oral IL-17 psoriasis program to a follow-up molecule. Lilly kicked DC ...

Of Lilly’s $3.11 billion in quarterly sales from Mounjaro, $2.4 billion came from the U.S. Related Compounders sue FDA for removing Eli Lilly's tirzepatide from shortage list ...

Eli Lilly (LLY) missed Wall Street's revenue expectations in its third quarter earnings released Wednesday morning, which sent shares down more than 6%. The drugmaker also slashed its profit ...